Alembic Pharmaceuticals secures USFDA approval for otic suspension
- Alembic Pharmaceuticals received USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%
- The generic is therapeutically equivalent to Sandoz Inc.'s Ciprodex Otic Suspension
- Target market size is estimated at $110 million for the twelve months ending June 2026
- The company now holds 246 cumulative ANDA approvals, including 226 final and 20 tentative
*this image is generated using AI for illustrative purposes only.
Alembic Pharmaceuticals has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Ciprofloxacin and Dexamethasone Otic Suspension USP, 0.3% / 0.1%. This regulatory clearance allows the company to market a generic equivalent to the reference listed drug product Ciprodex Otic Suspension in the United States.
The approved formulation is indicated for treating infections caused by susceptible isolates of designated microorganisms. Specifically, it addresses Acute Otitis Media (AOM) in pediatric patients aged six months and older with tympanostomy tubes, as well as Acute Otitis Externa (AOE) in pediatric, adult, and elderly patients aged six months and older.
Market Opportunity and Product Details
According to IQVIA data, the estimated market size for this specific suspension was $110 million for the twelve months ending June 2026. The product is therapeutically equivalent to the reference listed drug manufactured by Sandoz Inc., positioning Alembic to compete directly in this established therapeutic segment.
| Metric | Detail |
|---|---|
| Product | Ciprofloxacin and Dexamethasone Otic Suspension USP |
| Strength | 0.3% / 0.1% |
| Reference Drug | Ciprodex Otic Suspension (Sandoz Inc.) |
| Market Size | $110 million (12 months ending June 2026) |
| Indications | Acute Otitis Media (AOM), Acute Otitis Externa (AOE) |
Regulatory Milestones
This approval adds to Alembic's growing portfolio of regulatory clearances in the US. The company now holds a cumulative total of 246 ANDA approvals from the USFDA. This portfolio comprises 226 final approvals and 20 tentative approvals, reflecting the company's sustained focus on complex generics and regulatory compliance.
What the Numbers Show
The receipt of this final approval underscores Alembic's strategic focus on high-value niche markets within the broader anti-infective category. With the target market valued at $110 million, this single product launch represents a tangible opportunity for revenue diversification. Furthermore, the achievement of 246 cumulative ANDA approvals highlights the company's operational maturity in navigating US regulatory pathways, providing a robust pipeline foundation for future launches.
Historical Stock Returns for Alembic Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.40% | -1.38% | -4.28% | +7.44% | -13.97% | 0.0% |
How will Alembic's market entry impact the pricing dynamics and market share of existing competitors like Sandoz in the $110 million otic suspension segment?
What is the projected timeline for Alembic to achieve meaningful revenue contribution from this product launch, considering typical generic ramp-up periods?
Are there any pending patent challenges or exclusivity issues related to Ciprodex that could delay Alembic's commercialization or affect its long-term profitability?
17
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
